Stock 4169 TCM BIOTECH INTERNATIONAL CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials TCM Biotech International Corp.

Equities

4169

TW0004169008

Pharmaceuticals

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
55.7 TWD -0.36% Intraday chart for TCM Biotech International Corp. +10.08% -4.30%
Apr. 16 TCM Biotech International Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 TCM Biotech International Corp. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2022 2024
Capitalization 1 1,502 3,289
Enterprise Value (EV) 1 1,502 3,375
P/E ratio 80.6 x 77.4 x
Yield - 0.11%
Capitalization / Revenue - 3.04 x
EV / Revenue - 3.12 x
EV / EBITDA - 48.2 x
EV / FCF - -338 x
FCF Yield - -0.3%
Price to Book - 4.51 x
Nbr of stocks (in thousands) 49,049 59,049
Reference price 2 30.61 55.70
Announcement Date 4/21/23 -
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2024
Net sales 1 - 1,082
EBITDA 1 - 70
EBIT 1 - 45
Operating Margin - 4.16%
Earnings before Tax (EBT) 1 - 43
Net income 1 18.26 34
Net margin - 3.14%
EPS 2 0.3800 0.7200
Free Cash Flow 1 - -10
FCF margin - -0.92%
FCF Conversion (EBITDA) - -
FCF Conversion (Net income) - -
Dividend per Share 2 - 0.0600
Announcement Date 4/21/23 -
1TWD in Million2TWD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 S1 2024 S1 2024 S2 2025 S1 2025 S2 2026 S1
Net sales 1 465.2 523 559 583 774 991
EBITDA 1 21.92 33 38 - - -
EBIT 1 11.11 20 25 - - -
Operating Margin 2.39% 3.82% 4.47% - - -
Earnings before Tax (EBT) 1 9.857 19 24 - - -
Net income 1 8.424 15 19 - - -
Net margin 1.81% 2.87% 3.4% - - -
EPS 2 0.1800 0.3200 0.4000 0.6800 1.320 2.390
Dividend per Share - - - - - -
Announcement Date 8/11/23 - - - - -
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2024
Net Debt 1 - 86
Net Cash position 1 - -
Leverage (Debt/EBITDA) - 1.229 x
Free Cash Flow 1 - -10
ROE (net income / shareholders' equity) - 6%
ROA (Net income/ Total Assets) - 3.8%
Assets 1 - 894.7
Book Value Per Share 2 - 12.30
Cash Flow per Share 2 - -0.0900
Capex 1 - 4
Capex / Sales - 0.37%
Announcement Date 4/21/23 -
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for TCM Biotech International Corp.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
55.7 TWD
Average target price
113 TWD
Spread / Average Target
+102.87%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
TCM BIOTECH INTERNATIONAL CORP. Stock TCM Biotech International Corp.
-4.30% 101M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4169 Stock
  4. Financials TCM Biotech International Corp.